Prakt. lékáren. 2021; 17(3): e35-e43 [Klin Farmakol Farm. 2021;35(2):54-59]

Modern trends in pharmacological treatment heart failure

Jiří Vítovec, Jindřich Špinar, Lenka Špinarová

1. interní kardioangiologická klinika, Lékařská fakulta Masarykovy univerzity a Fakultní nemocnice u sv. Anny v Brně

ACE inhibitors and betablockers are the cornerstone of the treatment of heart failure, MRA should be added. Angiotensin receptor blockers (ARB) are indicated in the case of ACE inhibitors intolerance.  Renin angiotensin blockers and betablockers should be given in maximal tolerated doses. Diuretics are given to the symptoms relieve – dyspnoe or oedema. Digoxin is indicated in selected patients. There are 3 new promising groups of drugs: 1. Angiotensin Receptor-Neprilysin Inhibitor – ARNI – Sacubitril/Valsartan can replace the ACE-I according to the results of the PARADIGM-HF trial.  2. Sodium–glucose co-transporter-2 (SGLT2) inhibitors in patients with diabetes mellitus/prediabetes. 3. A hughe clinical research is done with omecamtiv mecarbil, vericiguat and other perspective drugs.

Keywords: heart failure, pharmacotherapy, ACE inhibitors, sartans, betablockers, diuretics, digoxin, sacubitril/valsartan, inhibitors SGLT2-gliflozins, omecamtiv mecarbil, vericiguat, new drugs.

Published: October 12, 2021  Show citation